MiniMed Bets Automated Insulin Delivery Can Cut Diabetes Decision Fatigue
MiniMed chief executive Que Dallara argues that insulin-dependent diabetes care remains too manual, with patients still making scores of dosing decisions each day. In a Bloomberg Technology interview after MiniMed’s IPO, Dallara said the former Medtronic Diabetes business is trying to become the “self-driving car” of diabetes care by combining sensors, pumps, pens and software into an automated insulin-management loop.
MiniMed’s public-company thesis is that insulin care is still too manual
For roughly 37 million people who manage diabetes with insulin, Que Dallara said care can still mean 8 to 10 injections a day and hundreds of dosing decisions. MiniMed’s public-company pitch is that much of that burden can be shifted from the patient to an automated system.
The company, formerly Medtronic Diabetes, has recently become public. Dallara framed that not as a new identity so much as a return to a familiar one: MiniMed had been public before Medtronic acquired it in 2001, and the brand remains well known in the diabetes community. As a standalone public company, she said, MiniMed can focus every day on diabetes innovation.
MiniMed is “uniquely positioned,” in Dallara’s account, because it has all the main components of an automated insulin-management system: glucose sensors, dosing devices such as smart pens and insulin pumps, and software that coordinates the automation. She called the software the “special secret sauce,” but described the operating model plainly: the sensor continuously measures glucose, the algorithm responds to movement in glucose levels, and the device delivers insulin doses every five minutes.
That matters because insulin dosing is not a simple response to food intake. Glucose management is affected by stress, hormones, illness, food, and “all sorts of factors,” with Dallara putting the number at 42. A person with diabetes is therefore making repeated decisions each day about when and how much to dose. MiniMed is trying to move more of those decisions into a continuous automated loop.
The burden is not only glucose control; it is decision fatigue
Dallara’s clearest explanation of the product was about cognitive load. The older state of the art, as she described it, was multiple daily injections: a person uses an insulin pen and must decide when to dose and how much insulin to take. That calculation repeats throughout the day under changing physical conditions.
MiniMed’s system is meant to run as a continuous loop. If glucose is rising, the system treats that as a signal that the person may be eating and calculates how much insulin to deliver. The pump then delivers insulin in five-minute increments. The point is not simply fewer injections, though Dallara emphasized that patients are no longer “poking” themselves 8 to 10 times daily. It is a transfer of some dosing judgment from the patient to the device.
We are trying to be the self-driving car of diabetes.
Dallara used the self-driving car analogy to describe MiniMed’s 10- to 15-year direction. A self-driving car takes a person from A to B without making them drive; MiniMed wants the patient to wear the device and let automation do the work. The target is not only better glucose outcomes but relief from the constant self-management that diabetes requires.
She put a number on that daily mental load: 180 decisions a day for someone with diabetes. Her examples were ordinary and practical. If she eats a panini, how much should she dose? If she has a meeting and expects glucose to rise, how should she respond without becoming confused? The company’s automation, in Dallara’s description, is designed to reduce both medical risk and the exhaustion of managing those questions continuously.
The medical target is staying in range, not merely avoiding emergencies
Que Dallara framed diabetes management as a dual problem: patients cannot go too low, because that is dangerous, and they cannot go too high, because sustained high glucose drives complications. She named brain damage and heart disease in that context, and earlier linked diabetes complications to cardiovascular disease, kidney disease, eye disease, and amputations.
The goal she emphasized is “time in range,” meaning the share of time glucose remains neither too low nor too high. Dallara cited the American Diabetes Association guideline as at least 70% time in range for people with diabetes. By comparison, she said, people without diabetes are in range about 95% of the time.
Automation is MiniMed’s path to that steadier level. The sensor detects glucose continuously; the software responds to changes; the pump doses frequently. The intended result is to help keep glucose within the narrow corridor between acute danger from lows and long-term complications from highs.
GLP-1 drugs do not alter that core exposure, Dallara said, because MiniMed focuses on people who already need insulin. Caroline Hyde raised the issue of whether GLP-1 innovation and broader health-management trends had changed MiniMed’s outlook. Dallara called GLP-1s “a fantastic therapy” for many people who can benefit from weight loss and healthier lives, but said they do not cure diabetes. MiniMed’s focus, she said, is insulin delivery for type 1 and type 2 diabetes. When insulin is required, MiniMed’s technology becomes relevant.
Adoption is still low, even where the technology is established
Despite describing automated insulin delivery as effective, Que Dallara said global adoption remains in the “low double digit” range. That leaves MiniMed with a commercial and educational problem: making people aware of the therapy, helping them start it, helping them stay on it, and making it easier to live without the burden of daily management.
MiniMed is already operating globally. The company is in 80 countries and has an installed base of more than 640,000 people using its therapies, according to Dallara. But access varies sharply by health system. She said the highest levels of automation are generally seen in the developed world, where health systems have funds to reimburse therapies. In the developing world, use tends to be out of pocket.
| Measure | Dallara's description |
|---|---|
| Countries | MiniMed operates in 80 countries |
| Installed base | More than 640,000 people globally use MiniMed therapies |
| Potential insulin-using population | About 37 million people manage diabetes with insulin |
| Global automation adoption | Low double digit range |
The work starts with clinical evidence. Approval is “just the start”; the company must persuade physicians and payers that the therapy works, explain how it is used, and help incorporate it into clinic workflows. That process, in her description, is ongoing and operational, not merely regulatory.
Dallara also connected the case for automation to the cost burden of diabetes. She said one quarter of U.S. healthcare spend is related to diabetes. Managing glucose up front, she argued, can alleviate downstream complications, including cardiovascular, kidney, and eye disease, as well as amputations. That is part of the message to health systems and payers: the cost of diabetes is not confined to glucose management itself.
Investors in diabetes technology are not the generalists Dallara expected
Que Dallara said investors who understand diabetes understand it “extremely deeply,” tracking clinical trials, FDA postings, market patterns, companies, and the direction of the technology.
Her example was deliberately vivid: sophisticated investors may spot a clinical trial posting on clinicaltrials.gov or the FDA website before employees inside a company are broadly aware of it. Rather than seeing diabetes technology as a niche category that must be translated for generalists, Dallara described it as a high-growth market with a knowledgeable audience and a history of “incredible returns.”
That investor story sits beside the clinical story. MiniMed’s public-company pitch is not just that insulin pumps are useful devices. It is that diabetes management is moving toward more integrated automation, and MiniMed believes it has the pieces required to operate that system: sensors, dosing devices, and software. The strategic objective is to reduce manual injections, increase time in range, and remove as many daily decisions as possible from people whose lives depend on getting those decisions right.